Nov 10, 2021 4:35pm EST DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2021 Financial Results
Nov 09, 2021 4:07pm EST DiaMedica Therapeutics to Attend the 12th Annual Craig-Hallum Alpha Select Conference November 16, 2021
Nov 08, 2021 8:35am EST DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial
Nov 04, 2021 8:30am EDT DiaMedica Therapeutics to Report Third Quarter 2021 Financial Results and Provide a Business Update November 11, 2021
Oct 18, 2021 8:30am EDT DiaMedica Therapeutics Announces Late Breaking Data from REDUX Phase 2 Trial to be Presented at ASN Kidney Week 2021
Sep 30, 2021 8:45am EDT DiaMedica Therapeutics Announces Fast Track Designation Granted to DM199 for the Treatment of Acute Ischemic Stroke
Sep 13, 2021 8:32am EDT DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke
